Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019

Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A(H1N1)pdm09 and lowe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kissling, Esther, Rose, Angela, Emborg, Hanne-Dorthe, Gherasim, Alin, Pebody, Richard, Pozo, Francisco, Trebbien, Ramona, Mazagatos, Clara, Whitaker, Heather, Valenciano, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2019
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446950/
https://www.ncbi.nlm.nih.gov/pubmed/30808440
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.1900121
_version_ 1783408441795018752
author Kissling, Esther
Rose, Angela
Emborg, Hanne-Dorthe
Gherasim, Alin
Pebody, Richard
Pozo, Francisco
Trebbien, Ramona
Mazagatos, Clara
Whitaker, Heather
Valenciano, Marta
author_facet Kissling, Esther
Rose, Angela
Emborg, Hanne-Dorthe
Gherasim, Alin
Pebody, Richard
Pozo, Francisco
Trebbien, Ramona
Mazagatos, Clara
Whitaker, Heather
Valenciano, Marta
author_sort Kissling, Esther
collection PubMed
description Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34–38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.
format Online
Article
Text
id pubmed-6446950
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-64469502019-04-17 Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019 Kissling, Esther Rose, Angela Emborg, Hanne-Dorthe Gherasim, Alin Pebody, Richard Pozo, Francisco Trebbien, Ramona Mazagatos, Clara Whitaker, Heather Valenciano, Marta Euro Surveill Rapid Communication Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34–38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season. European Centre for Disease Prevention and Control (ECDC) 2019-02-21 /pmc/articles/PMC6446950/ /pubmed/30808440 http://dx.doi.org/10.2807/1560-7917.ES.2019.24.1900121 Text en This article is copyright of the authors or their affiliated institutions, 2019. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Kissling, Esther
Rose, Angela
Emborg, Hanne-Dorthe
Gherasim, Alin
Pebody, Richard
Pozo, Francisco
Trebbien, Ramona
Mazagatos, Clara
Whitaker, Heather
Valenciano, Marta
Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019
title Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019
title_full Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019
title_fullStr Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019
title_full_unstemmed Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019
title_short Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019
title_sort interim 2018/19 influenza vaccine effectiveness: six european studies, october 2018 to january 2019
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446950/
https://www.ncbi.nlm.nih.gov/pubmed/30808440
http://dx.doi.org/10.2807/1560-7917.ES.2019.24.1900121
work_keys_str_mv AT kisslingesther interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT roseangela interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT emborghannedorthe interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT gherasimalin interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT pebodyrichard interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT pozofrancisco interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT trebbienramona interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT mazagatosclara interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT whitakerheather interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT valencianomarta interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019
AT interim201819influenzavaccineeffectivenesssixeuropeanstudiesoctober2018tojanuary2019

Ejemplares similares